KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

Abstract

In these real-life and population-based cohorts, there were no significant differences in patient characteristics and outcomes between patients with <i>KRAS-</i>G12C tumors and those with other <i>KRAS</i> mutations. This contrasts with the results of most previous studies claiming differences in many aspects, often with worse outcomes for those with a <i>KRAS-</i>G12C mutation, although not consistent. When specific drugs are developed, as for this mutation, differences in outcome will hopefully emerge.